KVP Capital Advisors, LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 18, 2026), KVP Capital Advisors, LP reported 25 stock positions worth $96.8 million. Its top holding was Terns Pharmaceuticals (TERN) at 18.4% of the portfolio, followed by Praxis Precision Medicines I (PRAX, 13.1%) and Axsome Therapeutics (AXSM, 6.8%).
- Most Recent 13F
- Q2 2026
- Location
- SAN FRANCISCO, CA
- CIK
- 0001858198
- Portfolio Value
- $96.8M (Q4 2025)
- SEC Filing
- 0001104659-26-016901 ↗ filed Feb 18, 2026
Holdings Value
Holdings 25 stocks · $96.8M
| TERN Terns Pharmaceuticals Inc. | 18.36% | 440,000 | $17.8M | — |
| PRAX Praxis Precision Medicines I | 13.06% | 42,900 | $12.6M | — |
| AXSM Axsome Therapeutics Inc. | 6.83% | 36,200 | $6.6M | — |
| WHWK Whitehawk Therapeutics Inc. | 5.41% | 2,165,997 | $5.2M | — |
| TRVI Trevi Therapeutics Inc. | 5.35% | 414,000 | $5.2M | — |
| INSM Insmed Inc. | 5.12% | 28,497 | $5.0M | — |
| PTGX Protagonist Therapeutics Inc. | 4.78% | 53,000 | $4.6M | — |
| IRON Disc Medicine Inc. | 4.78% | 58,250 | $4.6M | — |
| MBX MBX Biosciences Inc. | 3.96% | 121,524 | $3.8M | — |
| SVRA Savara Inc. | 3.77% | 605,280 | $3.6M | — |
| TVTX Travere Therapeutics Inc. | 3.59% | 91,000 | $3.5M | — |
| EWTX Edgewise Therapeutics Inc. | 3.41% | 133,000 | $3.3M | — |
| JAZZ Jazz Pharmaceuticals PLC | 3.07% | 17,500 | $3.0M | — |
| SLNO Soleno Therapeutics Inc. | 2.85% | 59,700 | $2.8M | — |
| UTHR United Therapeutics Corp. | 2.39% | 4,750 | $2.3M | — |
| ACHV Achieve Life Sciences Inc. | 2.37% | 462,355 | $2.3M | — |
| RVMD Revolution Medicines Inc. | 2.26% | 27,500 | $2.2M | — |
| SRRK Scholar Rock Holding Corp. | 2.05% | 45,000 | $2.0M | — |
| VERA Vera Therapeutics Inc. | 1.71% | 32,700 | $1.7M | — |
| IMMX Immix Biopharma Inc. | 1.24% | 230,423 | $1.2M | — |
| NKTR Nektar Therapeutics | 1.17% | 26,900 | $1.1M | — |
| CABA Cabaletta Bio Inc. | 1.14% | 505,431 | $1.1M | — |
| FULC Fulcrum Therapeutics Inc. | 0.58% | 50,000 | $566K | — |
| CELC Celcuity Inc. | 0.41% | 4,000 | $399K | — |
| VYNE THERAPEUTICS INC | 0.30% | 500,551 | $290K | — |
Options reported separately and not counted above: JAZZ PHARMACEUTICALS PLC calls ($5.3M), FULCRUM THERAPEUTICS INC calls ($1.3M).
Portfolio Sells Q4 2025
No earlier filing to compare with.
Portfolio Buys Q4 2025
No earlier filing to compare with.